格隆汇5月20日|美国医药公司再生元制药(Regeneron Pharmaceuticals)宣布,将以约2.6亿美元收购生物技术公司23andMe控股公司。根据协议,Regeneron将控制23andMe的个人基因组服务、全面健康和研究服务业务,以及其生物样本库和其他资产。此外,23andMe将继续正常提供其所有基因组服务。交易预计将于今年稍后时间完成,大约在第三季度,此后23andMe将成为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.